About Kashiv Specialty Pharmaceuticals
Kashiv Specialty Pharmaceuticals is a Healthcare company based in Bridgewater (United States) founded in 2020, and was acquired by Amneal in January 2021. Therapeutic solutions for rare diseases are developed. Kashiv Specialty Pharmaceuticals offers products and services including Drug Delivery Technologies. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its legal entity is Kashiv Specialty Pharmaceuticals, LLC. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Kashiv Specialty Pharmaceuticals was founded in 2020 and is based in Bridgewater, United States. Focus is placed on the pharmaceutical sector, where therapeutic solutions for rare diseases are developed. Operations include the advancement of drug candidate K127 for myasthenia gravis and skeletal muscle weakness. Additional candidates, such as K129 for ADHD, K128 for sialorrhea and movement disorders, and K114 for hypothyroidism, are created using proprietary drug delivery technology.
- Headquarters Bridgewater, United States
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website kashivsp.com
- Acquired by Amneal (Jan 2021)
- Legal Name Kashiv Specialty Pharmaceuticals, Llc
Products & Services of Kashiv Specialty Pharmaceuticals
Kashiv Specialty Pharmaceuticals offers a comprehensive portfolio of products and services, including Drug Delivery Technologies.
Innovative solutions for effective and specialized drug delivery methods.
Investors in Kashiv Specialty Pharmaceuticals
Kashiv Specialty Pharmaceuticals has secured backing from 1 investor. Prominent investors backing the company include Amneal.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | amneal.com | Bridgewater, United States |
Investor details for Kashiv Specialty Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Kashiv Specialty Pharmaceuticals
2 dated milestones of Kashiv Specialty Pharmaceuticals across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Kashiv Specialty Pharmaceuticals is founded.
- Exit Acquired by Amneal.
Competitors of Kashiv Specialty Pharmaceuticals
Kashiv Specialty Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Kashiv Specialty Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Kashiv Specialty Pharmaceuticals (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Kashiv Specialty Pharmaceuticals
Kashiv Specialty Pharmaceuticals was founded in 2020.
Kashiv Specialty Pharmaceuticals is headquartered in Bridgewater, United States. It is registered at Bridgewater, New Jersey, United States.
Kashiv Specialty Pharmaceuticals was founded in 2020 and is based in Bridgewater, United States. Focus is placed on the pharmaceutical sector, where therapeutic solutions for rare diseases are developed. Operations include the advancement of drug candidate K127 for myasthenia gravis and skeletal muscle weakness. Additional candidates, such as K129 for ADHD, K128 for sialorrhea and movement disorders, and K114 for hypothyroidism, are created using proprietary drug delivery technology.
Kashiv Specialty Pharmaceuticals's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Kashiv Specialty Pharmaceuticals offers Drug Delivery Technologies.
Kashiv Specialty Pharmaceuticals has 1 investor. Key investors include Amneal.
Kashiv Specialty Pharmaceuticals operates through Kashiv Specialty Pharmaceuticals, Llc.
Yes. Kashiv Specialty Pharmaceuticals was acquired by Amneal in January 2021.
